Dato-DXd + Osimertinib + Pemetrexed + Carboplatin + Cisplatin
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Non-small Cell Lung Cancer
Conditions
Metastatic Non-small Cell Lung Cancer
Trial Timeline
Oct 4, 2024 → Sep 27, 2028
NCT ID
NCT06417814About Dato-DXd + Osimertinib + Pemetrexed + Carboplatin + Cisplatin
Dato-DXd + Osimertinib + Pemetrexed + Carboplatin + Cisplatin is a phase 3 stage product being developed by Daiichi Sankyo for Metastatic Non-small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06417814. Target conditions include Metastatic Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Non-small Cell Lung Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06417814 | Phase 3 | Recruiting |
Competing Products
20 competing products in Metastatic Non-small Cell Lung Cancer